mebudipine profile

mebudipine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10407950
CHEMBL ID	1095098
MeSH ID	M0287175

Synonym
CHEMBL1095098
mebudipine
103521-70-6
5-o-tert-butyl 3-o-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Research Excerpts

Pharmacokinetics

After intravenous dosing, the plasma concentration of mebudipine declined biexponentially with a terminal half-life of 2. A suitable, convenient and simple HPLC assay was developed for pharmacokinetic study in rabbits.

Excerpt	Reference	Relevance
"A suitable, convenient and simple HPLC assay for pharmacokinetic study of mebudipine in rabbits was developed."	( High performance liquid chromatography of mebudipine: application to pharmacokinetic study. Bohlooli, S; Keyhanfar, F; Mahmoudian, M, )	0.63
" Pharmacokinetic study: plasma samples were collected periodically after intravenous (0."	( Application of a new high performance liquid chromatography method to the pharmacokinetics of dibudipine in rats. Bohlooli, S; Ghiaee, S; Keyhanfar, F; Mahmoudian, M, )	0.13

Bioavailability

A nanoemulsion drug delivery system was developed to increase the oral bioavailability of mebudipine. The aim of this investigation was to examine the efficacy of PhytoSolve and Phosal-based formulation (PBF)

Excerpt	Reference	Relevance
" Also, it appeared that mebudipine had a slower rate of absorption compared with nifedipine (the time to reach peak hypotensive action at 2, 4 and 8 mg kg(-1) orally administered doses were, respectively, 24."	( Effects of mebudipine and dibudipine, two new calcium-channel blockers, on rat left atrium, rat blood pressure and human internal mammary artery. Ghiaee, S; Mahmoudian, M; Mirkhani, H; Omrani, GR, 1999)	1
" Oral bioavailability was low."	( Application of a new high performance liquid chromatography method to the pharmacokinetics of dibudipine in rats. Bohlooli, S; Ghiaee, S; Keyhanfar, F; Mahmoudian, M, )	0.13
" The oral bioavailability was low (< 2%) suggesting a marked first-pass effect."	( Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. Bohlooli, S; Keyhanfar, F; Mahmoudian, M, 2004)	0.65
"The aim of this investigation was to examine the efficacy of PhytoSolve and Phosal-based formulation (PBF) to enhance the oral bioavailability of mebudipine, which is a poorly water-soluble calcium channel blocker."	( Improved oral bioavalability of mebudipine upon administration in PhytoSolve and Phosal-based formulation (PBF). Keyhanfar, F; Khani, S, 2014)	0.89
"A nanoemulsion drug delivery system was developed to increase the oral bioavailability of mebudipine as a calcium channel blocker with very low bioavailability profile."	( Design and evaluation of oral nanoemulsion drug delivery system of mebudipine. Amani, A; Keyhanfar, F; Khani, S, 2016)	0.89
"In this study, a nanoemulsion containing mebudipine [composed of ethyl oleate (oil phase), Tween 80 (T80), Span 80 (S80) (surfactants), polyethylene glycol 400, ethanol (cosurfactants), and deionized water] was prepared with the aim of improving its bioavailability for an effective antihypertensive therapy."	( Use of artificial neural networks for analysis of the factors affecting particle size in mebudipine nanoemulsion. Abbasi, S; Amani, A; Keyhanfar, F; Khani, S, 2019)	1

Dosage Studied

Excerpt	Relevance	Reference
" After oral dosing (10 mg/kg), the C(max) of mebudipine was 25."	( Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. Bohlooli, S; Keyhanfar, F; Mahmoudian, M, 2004)	0.91

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Mineralocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.1260	0.0003	0.7484	10.0000	AID478704; AID499835
Voltage-dependent L-type calcium channel subunit alpha-1C	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0200	0.0013	2.2495	6.9000	AID478705
Voltage-dependent L-type calcium channel subunit alpha-1D	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0200	0.0013	1.9915	10.0000	AID478705
Voltage-dependent L-type calcium channel subunit alpha-1S	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0200	0.0013	1.6020	6.9000	AID478705
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Mineralocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Mineralocorticoid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
DNA-binding transcription factor activity, RNA polymerase II-specific	Mineralocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Mineralocorticoid receptor	Homo sapiens (human)
nuclear steroid receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
steroid binding	Mineralocorticoid receptor	Homo sapiens (human)
protein binding	Mineralocorticoid receptor	Homo sapiens (human)
zinc ion binding	Mineralocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Mineralocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Mineralocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Mineralocorticoid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleoplasm	Mineralocorticoid receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Mineralocorticoid receptor	Homo sapiens (human)
cytosol	Mineralocorticoid receptor	Homo sapiens (human)
chromatin	Mineralocorticoid receptor	Homo sapiens (human)
receptor complex	Mineralocorticoid receptor	Homo sapiens (human)
nucleus	Mineralocorticoid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID499835	Antagonist activity at mineralocorticoid receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
AID478849	Antagonist activity at rat Cav1.3 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 200 nM by FLIPR calcium 4 assay	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
AID478854	Antagonist activity at rabbit Cav1.2 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 200 nM by FLIPR calcium 4 assay	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
AID478704	Antagonist activity at Gal4-fused mineralocorticoid receptor expressed in human HuH7 cells assessed as inhibition of aldosterone-induced receptor activation by luciferase reporter gene assay	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
AID478705	Inhibition of L-type calcium channel in rat A10 cells assessed as inhibition of depolarization-induced increase in calcium flux after 48 hrs by FLIPR assay	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
AID478859	Selectivity ratio of antagonist activity at rat Cav1.3 to antagonist activity at rabbit Cav1.2 at 200 nM	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (11.11)	18.2507
2000's	7 (38.89)	29.6817
2010's	8 (44.44)	24.3611
2020's	1 (5.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	21 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.03	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.05	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.	2.05	1	non-proteinogenic alpha-amino acid
4-aminopyridine [no description available]	2.01	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	7.45	2	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	9.18	16	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	2.05	1	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.05	1	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.02	1	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.05	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	2.05	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
galactose aldohexose : A hexose with a (potential) aldehyde group at one end.	2.21	1
barium chloride barium chloride: RN given refers to parent cpd. barium chloride : The inorganic dichloride salt of barium.	2.03	1	barium salt; inorganic chloride	potassium channel blocker
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.05	1	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester 1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester: structure given in first source	2.05	1
fr 7534 FR 7534: calcium antagonist structurally similar to nifedipine	2.05	1
diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate diethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate: structure in first source	2.05	1
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	2.46	2	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
D-fructopyranose [no description available]	2.1	1	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist	2.05	1	naphthalenes; sulfonic acid derivative
mtt formazan MTT formazan: a blue MEM-insoluble mitochondrial byproduct; used to determine viability of cells with active mitochondrial dehydrogenase enzymes	2.05	1
ethyl oleate [no description available]	2.21	1	long-chain fatty acid ethyl ester	acaricide; plant metabolite
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.05	1	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
pranidipine pranidipine: structure given in UD 37:228m	2.05	1
formazans Formazans: Colored azo compounds formed by the reduction of tetrazolium salts. Employing this reaction, oxidoreductase activity can be determined quantitatively in tissue sections by allowing the enzymes to act on their specific substrates in the presence of tetrazolium salts.	2.05	1
sorbitan monooleate [no description available]	2.21	1	fatty acid ester
dibudipine dibudipine: structure in first source	3.63	9

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.31	1
Cardiac Failure [description not available]	2.31	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	7.31	1
Arrhythmia [description not available]	7.13	1
Injury, Ischemia-Reperfusion [description not available]	2.48	2
Atrioventricular Nodal Re-Entrant Tachycardia [description not available]	2.13	1
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	2.13	1
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	2.13	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.48	2
Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).	2.13	1
Anoxemia [description not available]	2.05	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.05	1
Alloxan Diabetes [description not available]	2.05	1
Diabetic Glomerulosclerosis [description not available]	2.05	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.05	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.41	2
Angor Pectoris [description not available]	2.02	1
Blood Pressure, High [description not available]	2.02	1
Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.	2.02	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.02	1
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	1.99	1

mebudipine

Description

Cross-References

Synonyms (4)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (4)

Inhibition Measurements

Biological Processes (4)

Molecular Functions (10)

Ceullar Components (6)

Bioassays (6)

Research

Studies (18)

Study Types

mebudipine

Description

Cross-References

Synonyms (4)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (4)

Inhibition Measurements

Biological Processes (4)

Molecular Functions (10)

Ceullar Components (6)

Bioassays (6)

Research

Studies (18)

Study Types

Related Drugs (27)

Related Conditions (21)